FDA Accepts New Schizophrenia Drug, May End Patient Monitoring Burden

PARSIPPANY, NJ – February 20, 2026 – The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application for an investigational schizophrenia treatment that could fundamentally change the therapeutic landscape for thousands of patients. Teva Pharmaceuticals and French biopharma company Medincell announced the regulatory milestone for TEV-'749, a once-monthly, extended-release injectable suspension of olanzapine, one of the most widely prescribed antipsychotics for adults with schizophrenia.

The drug's potential lies not just in its convenient monthly dosing but in its promise to eliminate a significant barrier to care: the mandatory three-hour post-injection monitoring period required for the only currently available long-acting olanzapine formulation. This development marks a critical step toward addressing treatment adherence, a persistent and costly challenge in managing the chronic mental disorder.

A Breakthrough for Patients and Caregivers

For individuals living with schizophrenia, medication adherence is a lifeline. The condition, which affects how a person thinks, feels, and acts, is marked by episodes of psychosis that can be managed with consistent treatment. However, studies show that approximately 80% of patients experience multiple relapses within the first five years, often due to interruptions in their medication regimen. Each relapse carries a biological risk, potentially leading to loss of function and treatment resistance.

Long-acting injectable (LAI) antipsychotics have emerged as a key strategy to combat non-adherence, replacing the need for daily pills with injections administered every few weeks or months. While effective, the current long-acting version of olanzapine, Zyprexa Relprevv, comes with a significant drawback. Due to a rare but serious side effect known as post-injection delirium/sedation syndrome (PDSS), its use is governed by a strict FDA-mandated Risk Evaluation and Mitigation Strategy (REMS). This program requires the injection to be administered in a certified healthcare facility, followed by three hours of professional observation, creating a logistical and time-consuming burden for both patients and healthcare providers.

TEV-'749 aims to solve this problem. The NDA submission is supported by data from the Phase 3 SOLARIS trial, a large-scale study involving 675 patients. Crucially, across 3,470 injections administered over 56 weeks, there were zero reported cases of PDSS. This strong safety signal suggests the drug may not require the restrictive REMS monitoring, a point emphasized by Teva’s leadership.

“Treatment adherence remains a major challenge and unmet need for people living with schizophrenia,” said Eric Hughes, MD, PhD, Executive Vice President at Teva. He noted that the investigational drug “has the potential to help provide stability by offering the proven efficacy and safety of olanzapine as a once-monthly treatment.”

The ability to receive an effective olanzapine treatment without the lengthy observation period would represent a profound improvement in quality of life. It would reduce time spent in clinics, lessen the impact on work and family schedules, and lower the overall barrier to receiving consistent care, which experts believe could significantly improve long-term outcomes.

The Science Behind Stability: Medincell's SteadyTeq™ Platform

At the heart of this potential breakthrough is an innovative drug delivery technology. TEV-'749 utilizes SteadyTeq™, a proprietary copolymer platform developed by Medincell. The technology, which Medincell calls BEPO®, involves formulating the active drug within a biocompatible polymer solution.

When injected subcutaneously (just under the skin), the solution forms a small, fully bioresorbable deposit. This depot acts as a micropump, steadily releasing the olanzapine into the bloodstream at a controlled, therapeutic level over the course of a month. By precisely managing the release kinetics, the technology is designed to avoid the rapid drug spikes that are believed to cause PDSS with the existing intramuscular formulation.

This FDA acceptance serves as a powerful second validation for Medincell’s platform. In April 2023, the agency approved UZEDY®, a long-acting injectable of risperidone for schizophrenia that also uses the SteadyTeq™ technology and is commercialized by Teva. The continued success of the platform positions Medincell as a key innovator in the lucrative and rapidly growing field of long-acting therapeutics.

“Daily olanzapine is one of the most widely prescribed antipsychotics for people living with schizophrenia, and this long‑acting formulation may better fit into their lives,” said Christophe Douat, CEO of Medincell. “As experience with long‑acting injectables continues to grow, they are increasingly recognized as an important treatment option in serious psychiatric conditions.”

Reshaping Schizophrenia Care and Costs

The implications of a more accessible long-acting olanzapine extend beyond individual patient benefits to the healthcare system as a whole. The global market for LAI antipsychotics reached approximately $5.3 billion in 2024 and is projected to double to $10.6 billion by 2033, driven by a growing recognition of their role in improving adherence and reducing costly relapses.

Schizophrenia carries a significant economic burden, largely due to costs associated with emergency care and hospitalizations following a relapse. By making a highly effective antipsychotic available in a more convenient and less burdensome format, TEV-'749 could help stabilize patients and prevent the cycle of crisis and rehospitalization. The SOLARIS trial data supports this potential, showing that TEV-'749 produced clinically meaningful and statistically significant reductions in schizophrenia symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS).

If approved, TEV-'749 would enter a competitive but expanding market, offering a unique value proposition. It would provide clinicians and patients with access to the well-established benefits of olanzapine in a format that overcomes the primary obstacle that has limited its long-acting use for years. The FDA's review of the application will be closely watched by patients, clinicians, and competitors, as its approval could set a new standard of care and capture a significant share of the LAI market by filling a long-standing treatment gap.